+

WO2002011674A3 - Procede et reactif permettant d'inhiber le canal chlorure active par le calcium 1 (clca-1) - Google Patents

Procede et reactif permettant d'inhiber le canal chlorure active par le calcium 1 (clca-1) Download PDF

Info

Publication number
WO2002011674A3
WO2002011674A3 PCT/US2001/024970 US0124970W WO0211674A3 WO 2002011674 A3 WO2002011674 A3 WO 2002011674A3 US 0124970 W US0124970 W US 0124970W WO 0211674 A3 WO0211674 A3 WO 0211674A3
Authority
WO
WIPO (PCT)
Prior art keywords
chloride channel
clca
inhibition
reagent
calcium activated
Prior art date
Application number
PCT/US2001/024970
Other languages
English (en)
Other versions
WO2002011674A2 (fr
Inventor
James Mcswiggen
James Thompson
Timothy Mckenzie
David Ayers
David E Szymkowski
Andrew Grupe
Original Assignee
Ribozyme Pharm Inc
Syntex Llc
James Mcswiggen
James Thompson
Timothy Mckenzie
David Ayers
David E Szymkowski
Andrew Grupe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribozyme Pharm Inc, Syntex Llc, James Mcswiggen, James Thompson, Timothy Mckenzie, David Ayers, David E Szymkowski, Andrew Grupe filed Critical Ribozyme Pharm Inc
Priority to AU2001283222A priority Critical patent/AU2001283222A1/en
Publication of WO2002011674A2 publication Critical patent/WO2002011674A2/fr
Publication of WO2002011674A3 publication Critical patent/WO2002011674A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des molécules d'acide nucléique, notamment des molécules d'acide nucléique antisens et enzymatiques telles que les ribozymes en tête de marteau, les ADNzymes et les GeneBlocs, qui modulent l'expression des canaux chlorure activés par le calcium (CLCA1, CLCA2, CLCA3, et CLCA4).
PCT/US2001/024970 2000-08-09 2001-08-09 Procede et reactif permettant d'inhiber le canal chlorure active par le calcium 1 (clca-1) WO2002011674A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001283222A AU2001283222A1 (en) 2000-08-09 2001-08-09 Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22438300P 2000-08-09 2000-08-09
US60/224,383 2000-08-09

Publications (2)

Publication Number Publication Date
WO2002011674A2 WO2002011674A2 (fr) 2002-02-14
WO2002011674A3 true WO2002011674A3 (fr) 2003-09-25

Family

ID=22840434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024970 WO2002011674A2 (fr) 2000-08-09 2001-08-09 Procede et reactif permettant d'inhiber le canal chlorure active par le calcium 1 (clca-1)

Country Status (2)

Country Link
AU (1) AU2001283222A1 (fr)
WO (1) WO2002011674A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149599A0 (en) * 1999-11-24 2002-11-10 Takeda Chemical Industries Ltd Use of disease-associated gene
MXPA05012728A (es) * 2003-05-28 2006-02-13 Wyeth Corp Clca-1 soluble y antagonistas para el clca-1.
EP3263115A1 (fr) * 2016-06-30 2018-01-03 Technische Hochschule Mittelhessen Invention concernant un agent actif contre le pseudomonas aeruginosa

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011304A1 (fr) * 1993-10-18 1995-04-27 Ribozyme Pharmaceuticals, Inc. Adn catalytique
WO1997026270A2 (fr) * 1996-01-16 1997-07-24 Ribozyme Pharmaceuticals, Inc. Synthese de methoxy nucleosides et de molecules d'acide nucleique enzymatique
WO1998032846A2 (fr) * 1997-01-23 1998-07-30 Ribozyme Pharmaceuticals, Inc. Traitement par acides nucleiques enzymatiques des maladies ou des etats lies aux niveaux de c-fos
WO1999055857A2 (fr) * 1998-04-29 1999-11-04 Ribozyme Pharmaceuticals, Inc. Nucleoside triphosphates et leur integration aux ribozymes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011304A1 (fr) * 1993-10-18 1995-04-27 Ribozyme Pharmaceuticals, Inc. Adn catalytique
WO1997026270A2 (fr) * 1996-01-16 1997-07-24 Ribozyme Pharmaceuticals, Inc. Synthese de methoxy nucleosides et de molecules d'acide nucleique enzymatique
WO1998032846A2 (fr) * 1997-01-23 1998-07-30 Ribozyme Pharmaceuticals, Inc. Traitement par acides nucleiques enzymatiques des maladies ou des etats lies aux niveaux de c-fos
WO1999055857A2 (fr) * 1998-04-29 1999-11-04 Ribozyme Pharmaceuticals, Inc. Nucleoside triphosphates et leur integration aux ribozymes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COUTURE L A ET AL: "Anti-gene therapy: the use of ribozymes to inhibit gene function", TRENDS IN GENETICS, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 12, no. 12, 1 December 1996 (1996-12-01), pages 509, XP004071051, ISSN: 0168-9525 *
DATABASE GENBANK [online] 14 December 1998 (1998-12-14), "Homo sapiens calcium-dependent chloride channel-1 (hCLCA1) mRNA, complete cds", XP002219572, Database accession no. AF039400 *
GRUBER A D ET AL: "GENOMIC CLONING, MOLECULAR CHARACTERIZATION, AND FUNCTIONAL ANALYSIS OF HUMAN CLCA1, THE FIRST HUMAN MEMBER OF THE FAMILY OF CA2+-ACTIVATED CI CHANNEL PROTEINS", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 54, 1998, pages 200 - 214, XP002945247, ISSN: 0888-7543 *
LUDWIG J ET AL: "Extending the cleavage rules for the hammerhead ribozyme: mutating adenosine15.1 to inosine15.1 changes the cleavage site specificity from N16.2U16.1H17 to N16.2C16.1H17", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 26, no. 10, 15 May 1998 (1998-05-15), pages 2279 - 2285, XP002084035, ISSN: 0305-1048 *
VAISH ET AL: "In vitro selection of a purine nucleotide-specific hammerhead-like ribozyme", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, no. 5, 1 March 1998 (1998-03-01), pages 2158 - 2162, XP002097465, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2002011674A2 (fr) 2002-02-14
AU2001283222A1 (en) 2002-02-18

Similar Documents

Publication Publication Date Title
WO2003073999A3 (fr) Composes de modulation de pin1 et procedes d'utilisation correspondant
WO2003074550A3 (fr) Composes de modulation de pin1 et procedes d'utilisation correspondant
WO1999046372A3 (fr) Ribozymes capables d'inhiber l'expression du recepteur ccr5
EP1263765A4 (fr) Modification de comportement cellulaire par modulation antisens de la maturation d'arn messager
GB0404561D0 (en) Active controlled bottomhole pressure system & method background of the invention
MXPA03001001A (es) Derivados anticonvulsionantes utiles para el tratameinto de la depresion.
WO2002083105A3 (fr) Composition pour une meilleure absorption d'anti-inflammatoires non steroidiens
WO2002030353A3 (fr) INHIBITEURS DU NF-λB
WO2002072736A3 (fr) Demulsification d'emulsions d'eau dans l'huile
AU2002227442A1 (en) Method for the prevention, inhibition, or treatment of vaginitis and/or bacterial vaginosis using polystyrene sulfonate
WO2002026968A3 (fr) Acides nucleiques iap antisens et utilisations associees
AU8661201A (en) Method, system and shoe enabling the determination of fit from outside of the shoe
EG23184A (en) Targeting system and method of targeting.
WO2001057206A3 (fr) Procede et reactif destines a inhiber la checkpoint kinase-1 (chk 1)
WO2005007123A3 (fr) Composes modulateurs de pin-1 et methodes d'utilisation associees
MXPA03001717A (es) METODO PARA EL TRATAMIENTO DE LA MIGRAnA.
WO2001088124A3 (fr) Procede et reactif destine a l'inhibition d'erg
ZA200306124B (en) Method of treating of demyelinating diseases or conditions.
WO2001087287A3 (fr) Composes actifs sur le plan pharmaceutiques et procedes d'utilisation
MXPA02012907A (es) Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxia de la obesidad.
WO2002018590A3 (fr) Identification de recepteurs et de canaux ioniques actives
WO2000032765A3 (fr) Ribozymotherapie destinee au traitement et/ou a la prevention de la restenose
WO2001028493A3 (fr) Inhibiteurs a petite molecule de la necrose
WO2002011674A3 (fr) Procede et reactif permettant d'inhiber le canal chlorure active par le calcium 1 (clca-1)
WO2003070169A3 (fr) Modulateurs d'apolipoproteine e a base d'aminodiphosphonate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载